Oxytocin treatment in children with Prader-Willi syndrome: A double-blind, placebo-controlled, crossover study

Jennifer L Miller1, Roy Tamura2, Merlin G Butler3

  • 1Departmentof Pediatrics College of Medicine, University of Florida, Gainesville, Florida.

Insights

Intranasal oxytocin (IN-OT) shows promise as a safe treatment for Prader-Willi syndrome (PWS). This study suggests IN-OT may reduce appetite and improve social behaviors, anxiety, and repetitive actions in individuals with PWS.

Area of Science:

  • Neuroendocrinology
  • Genetics
  • Pediatric Medicine

Background:

  • Prader-Willi syndrome (PWS) is a complex genetic disorder characterized by hypothalamic dysfunction, hyperphagia, and behavioral issues.
  • Individuals with PWS exhibit a deficit in oxytocin-producing neurons, impacting feeding, social interaction, and emotional regulation.
  • Oxytocin's role in regulating key behaviors affected by PWS necessitates investigation into its therapeutic potential.

Purpose of the Study:

  • To evaluate the safety and efficacy of intranasal oxytocin (IN-OT) in children with Prader-Willi syndrome.
  • To assess the impact of IN-OT on hyperphagia, social behaviors, anxiety, and repetitive behaviors in PWS patients.
  • To determine the short-term effects of IN-OT compared to placebo in a pediatric PWS population.

Main Methods:

  • A double-blind, placebo-controlled, crossover study involving 24 children with PWS.
  • Participants received either 5 days of IN-OT or placebo, followed by a 4-week washout, then the alternate treatment.
  • Evaluations included standardized behavioral questionnaires, Clinical Global Impression scales, safety labs, and dietary assessments.

Main Results:

  • Improvements in various behavioral and clinical factors from Day 3 to Day 6 favored oxytocin over placebo.
  • No statistically significant differences were observed between groups at Day 6 for any single factor.
  • Observed drug effects diminished by Day 14, with no significant safety concerns or changes in weight or diet parameters.

Conclusions:

  • Low-dose intranasal oxytocin appears safe for individuals with Prader-Willi syndrome.
  • IN-OT may offer potential benefits in reducing appetite drive and improving socialization, anxiety, and repetitive behaviors.
  • Further long-term studies with larger cohorts are required to confirm these preliminary findings and establish efficacy.

Related Concept Videos

Blind Procedures02:07

Blind Procedures

Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which child was...